Metrics to compare | XLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipXLSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.8x | 5.1x | −0.4x | |
PEG Ratio | 0.03 | 0.04 | 0.00 | |
Price/Book | 0.4x | 1.9x | 2.6x | |
Price / LTM Sales | 372.8x | 3.6x | 3.0x | |
Upside (Analyst Target) | 177.8% | 5.0% | 54.6% | |
Fair Value Upside | Unlock | 2.8% | 9.7% | Unlock |
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company’s project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinical research services. It also develops novel treatment options in specific indication areas; focuses in the areas of medical technology to develop innovative methods for diagnosing illnesses and/or patient monitoring; and deploys artificial intelligence to improve diagnostic methods and/or processes in the field of biotechnology. Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.